LeMaitre Vascular (LMAT) director gains shares from dividend rights

Rhea-AI Filing Summary

LeMaitre Vascular, Inc. disclosed that a director acquired common stock through the vesting of equity-based awards on 12/12/2025. Two transactions converted derivative awards into common stock, each for 5 shares of common stock at a price of $0 per share under transaction code "M," which typically reflects the exercise or conversion of derivative securities.

The new shares came from the release of dividend equivalent rights that were tied to restricted stock unit and performance stock unit awards originally granted on 12/12/2022. Each dividend equivalent right was the economic equivalent of one share of LeMaitre Vascular common stock, and any fractional shares were settled in cash, leaving no remaining dividend equivalent rights outstanding after these vesting events.

Insider Trade Summary

10 shares exercised/converted

Mixed 4 txns

Insider SHADAN MARTHA

Role Director

Type	Security	Shares	Price	Value
Exercise	Dividend Equivalent Rights	5	$0.00	--
Exercise	Dividend Equivalent Rights	5	$0.00	--
Exercise	Common Stock	5	$0.00	--
Exercise	Common Stock	5	$0.00	--

Holdings After Transaction: Dividend Equivalent Rights — 0 shares (Direct); Common Stock — 2,480 shares (Direct)

Footnotes (1)

1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. Fractional shares (if any) were settled in cash on each vesting date, resulting in a final balance of zero. These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHADAN MARTHA

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		M		5(1)	A	$0(1)	2,480	D
Common Stock	12/12/2025		M		5(1)	A	$0(1)	2,485	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(2)	12/12/2025		M			5(2)	(2)	(2)	Common Stock	5	$0	0(3)	D
Dividend Equivalent Rights	(4)	12/12/2025		M			5(4)	(4)	(4)	Common Stock	5	$0	0(3)	D

Explanation of Responses:

1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

2. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. Fractional shares (if any) were settled in cash on each vesting date, resulting in a final balance of zero.

4. These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transaction did LMAT report in this document?

A director of LeMaitre Vascular, Inc. (LMAT) reported acquiring common stock when equity awards vested on 12/12/2025. Two transactions each converted 5 dividend equivalent rights into 5 shares of common stock at a price of $0 per share.

How were the newly acquired LMAT shares generated for the director?

The shares were acquired through the release of dividend equivalent rights linked to earlier equity awards. When the awards vested, each right, which was the economic equivalent of one share of common stock, converted into one share of LeMaitre Vascular common stock.

Which equity awards for LMAT generated these dividend equivalent rights?

The dividend equivalent rights were released in connection with the vesting of a restricted stock unit award and a performance stock unit award, both originally granted on 12/12/2022. Each award generated dividend equivalent rights that tracked the value of LeMaitre Vascular common stock.

What happened to the dividend equivalent rights after the LMAT awards vested?

Upon vesting on 12/12/2025, the dividend equivalent rights were converted into shares of LeMaitre Vascular common stock on a one-for-one basis. Any fractional shares that resulted were settled in cash, resulting in a final balance of zero dividend equivalent rights remaining.

What is the relationship of the reporting person to LeMaitre Vascular (LMAT)?

The reporting person is a director of LeMaitre Vascular, Inc., as indicated by the relationship selection on the form. The filing is made as a Form filed by one reporting person, reflecting this individual insider’s equity transactions.

Were any cash payments made by the director to acquire the LMAT shares?

The transactions list a price of $0 per share for the common stock acquired through the conversion of dividend equivalent rights. This indicates the shares were received as part of the vesting of equity awards rather than purchased on the open market.